Matinas Biopharma Holdings, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
AMEX
Adam K. Stern and affiliated entities have updated their Schedule 13D filing to reflect the exercise of warrants and the acquisition of new warrants in Matinas BioPharma Holdings, Inc., increasing beneficial ownership.
AMEX
Hezbay Holdings LLC and Ari Kluger have withdrawn from a joint filing agreement regarding their stake in Matinas BioPharma Holdings, Inc. due to personal reasons.
AMEX
SCHEDULE 13D/A: Matinas BioPharma Investors Increase Stake, Acquire Significant Convertible Securities
A group of investors, including Sanitam Partners LLC, Platinum Point Capital, LLC, and HEZBAY Holdings LLC, have completed a second closing of a purchase agreement with Matinas BioPharma Holdings, Inc., acquiring additional preferred stock and warrants, while adhering to a 9.99% beneficial ownership cap.
AMEX
SCHEDULE 13D/A: Matinas BioPharma Holdings Amends 13D Filing, Details Increased Stake and Ownership Caps for Key Investors
Matinas BioPharma Holdings, Inc. has filed an amendment to its Schedule 13D, detailing the second closing of a private placement that significantly increases the potential beneficial ownership of Pembroke & Partners LLC and Robert J. Eide, subject to a 9.99% beneficial ownership cap.
AMEX
Pembroke & Partners LLC and Robert J. Eide have disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquiring preferred stock and warrants in a private placement, with intentions to actively engage with management and potentially seek board representation.
AMEX
SCHEDULE 13D: Investment Group Discloses Significant Stake in Matinas BioPharma, Seeks Board Representation
A group of investors, including Sanitam Partners LLC, HEZBAY Holdings LLC, and Platinum Point Capital, LLC, has disclosed a significant beneficial ownership stake in Matinas BioPharma Holdings, Inc., acquired through a private placement of convertible preferred stock and warrants, with plans to seek board representation.
AMEX
SCHEDULE 13D/A: Activist Investors Disclose 3.61% Stake in Matinas Biopharma, Signal Intent for Value Enhancement
Chaim Herzog and 111 Equity Group LLC have filed an amended Schedule 13D, revealing a 3.61% beneficial ownership in Matinas Biopharma Holdings, Inc. and indicating potential discussions regarding the company's strategy and governance.
AMEX
Chaim Herzog and 111 Equity Group LLC have disclosed a 5.17% beneficial ownership stake in Matinas Biopharma Holdings, Inc., intending to engage with management on strategic alternatives including asset sales, reverse mergers, or dissolution, following the company's cessation of product development.